| Disease Domain | Count |
|---|---|
| Neoplasms | 3 |
| Infectious Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
Target |
Mechanism ENPP3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ENPP1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CA1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2023 |
Sponsor / Collaborator [+3] |
Start Date15 Sep 2018 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Compound 5l(Bahauddin Zakariya University) ( CD39 ) | Inflammation More | Preclinical |
Compound 5m(Bahauddin Zakariya University) ( ENTPD2 ) | Inflammation More | Preclinical |
Compound 3h(Bahauddin Zakariya University) ( ENPP1 ) | Neoplasms More | Preclinical |
Compound 3e(Bahauddin Zakariya University) ( ENPP3 ) | Neoplasms More | Preclinical |
Novel 4-Propylsulfonylpiperazines-Based Thiosemicarbazones(Bahauddin Zakariya University) ( CD39 x CD39L3 x CD73 x ENTPD2 ) | Inflammation More | Discovery |





